John Heymach, MD, PhD

home / authors / john-heymach-md-phd

Articles

Changing Landscape of EGFR+ mNSCLC

Changing Landscape of EGFR+ mNSCLC

John Heymach, MD, PhD
May 21st 2020
Repeat Testing at Progression of EGFR+ NSCLC

Repeat Testing at Progression of EGFR+ NSCLC

John Heymach, MD, PhD
May 21st 2020
Manageable Adverse Effects Associated With Treatments for EGFR+ NSCLC

Manageable Adverse Effects Associated With Treatments for EGFR+ NSCLC

John Heymach, MD, PhD
May 21st 2020
Practical Implications of the RELAY Trial in EGFR+ NSCLC

Practical Implications of the RELAY Trial in EGFR+ NSCLC

John Heymach, MD, PhD
May 21st 2020
Treatment Options for EGFR+ NSCLC

Treatment Options for EGFR+ NSCLC

John Heymach, MD, PhD
May 21st 2020
Molecular Testing for Newly Diagnosed NSCLC

Molecular Testing for Newly Diagnosed NSCLC

John Heymach, MD, PhD
May 21st 2020
Improved Outcomes for Patients With EGFR+ NSCLC

Improved Outcomes for Patients With EGFR+ NSCLC

John Heymach, MD, PhD
May 21st 2020
A 68-Year-Old Man With Metastatic EGFR+ NSCLC

A 68-Year-Old Man With Metastatic EGFR+ NSCLC

John Heymach, MD, PhD
May 21st 2020
A 68-Year-Old Man With Metastatic EGFR+ NSCLC

A 68-Year-Old Man With Metastatic EGFR+ NSCLC

John Heymach, MD, PhD
May 21st 2020

John Heymach, MD, reviews the evolving treatment landscape of EGFR+ metastatic non-small cell lung cancer.

Characteristics of Additional KRAS Subsets in Lung Cancer

Characteristics of Additional KRAS Subsets in Lung Cancer

John Heymach, MD, PhD
May 13th 2015

John Heymach, MD, PhD, chair of Thoracic/Head and Neck Medical Oncology, MD Anderson Cancer Center, discusses the characteristics of three more KRAS subsets in lung cancer, which researchers discovered in a recent study.

Latest Updated Articles

ASH 2024 Preview for Community Oncologists: The Show and After Show
Published: December 3rd 2024 | Updated: December 6th 2024
ASH 2024 Preview for Community Oncologists: The Show and After Show
FDA Accepts BLA for Subcutaneous Nivolumab Across Various Solid Tumors
Published: May 6th 2024 | Updated: May 21st 2024
FDA Accepts BLA for Subcutaneous Nivolumab Across Various Solid Tumors
POLL: What Frontline Treatment Would You Choose for Favorable- and Intermediate-Risk RCC?
Published: August 29th 2022 | Updated: December 23rd 2024
POLL: What Frontline Treatment Would You Choose for Favorable- and Intermediate-Risk RCC?
Immunotherapy Options for an Older Patient With Metastatic Melanoma
Published: August 18th 2023 | Updated: December 23rd 2024
Immunotherapy Options for an Older Patient With Metastatic Melanoma
Reviewing the Choice of First-Line Combinations for Clear Cell RCC and Other Histologies
Published: July 15th 2022 | Updated: December 23rd 2024
Reviewing the Choice of First-Line Combinations for Clear Cell RCC and Other Histologies
Emerging data on oral selective estrogen receptor degraders
Published: November 25th 2024 | Updated: December 23rd 2024
Emerging data on oral selective estrogen receptor degraders